Overview
Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate. Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. Cisatracurium is an R-cis-R-cis isomer of atracurium and has approximately 3 times its neuromuscular blocking potency. Compared to atracurium, cisatracurium produces a lower degree of histamine release.
Indication
Cisatracurium is indicated as an adjunct to general anesthesia to facilitate tracheal intubation in adults and pediatric patients 1 month to 12 years of age. Cisatracurium is also indicated to provide skeletal muscle relaxation during surgery in adults and pediatric patients 2 to 12 years of age as a bolus or infusion maintenance and for mechanical ventilation in the ICU in adults.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/07/23 | Not Applicable | Recruiting | Southeast University, China | ||
2024/01/19 | Not Applicable | Completed | Watim Medical & Dental College | ||
2024/01/12 | Not Applicable | Recruiting | |||
2023/10/26 | N/A | Completed | Institut Jantung Negara | ||
2023/03/09 | Not Applicable | Recruiting | Yangzhou University | ||
2022/11/22 | Phase 4 | Not yet recruiting | Second Affiliated Hospital of Nanchang University | ||
2022/09/02 | Not Applicable | Completed | Second Affiliated Hospital of Nanchang University | ||
2022/04/04 | Not Applicable | Completed | Chang Gung Memorial Hospital | ||
2021/12/29 | Not Applicable | UNKNOWN | |||
2021/12/10 | Phase 4 | UNKNOWN |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Zydus Lifesciences Limited | 72785-0009 | INTRAVENOUS | 10 mg in 1 mL | 11/5/2022 | |
Meitheal Pharmaceuticals Inc. | 71288-712 | INTRAVENOUS | 10 mg in 5 mL | 4/20/2023 | |
Teva Parenteral Medicines, Inc. | 0703-2045 | INTRAVENOUS | 200 mg in 20 mL | 11/28/2023 | |
Eugia US LLC | 55150-284 | INTRAVENOUS | 10 mg in 5 mL | 4/27/2023 | |
Sandoz Inc | 0781-3150 | INTRAVENOUS | 2 mg in 1 mL | 4/26/2017 | |
Hospira, Inc. | 0409-7083 | INTRAVENOUS | 2 mg in 1 mL | 12/5/2022 | |
Meitheal Pharmaceuticals Inc. | 71288-714 | INTRAVENOUS | 20 mg in 10 mL | 5/31/2019 | |
PIRAMAL CRITICAL CARE INC | 66794-246 | INTRAVENOUS | 200 mg in 20 mL | 8/9/2023 | |
PIRAMAL CRITICAL CARE INC | 66794-245 | INTRAVENOUS | 10 mg in 5 mL | 8/9/2023 | |
Somerset Therapeutics, LLC | 70069-161 | INTRAVENOUS | 2 mg in 1 mL | 6/7/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
Nimbex Forte Injection 150 mg/30 ml | SIN14310P | INJECTION, SOLUTION | 150 mg/30 ml | 2/5/2013 | |
Nimbex Injection 2 mg/ml | SIN14309P | INJECTION, SOLUTION | 2 mg/ml | 2/5/2013 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
No Health Canada approvals found for this drug. |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.